Pharmacological activation of cloned intermediate- and small-conductance Ca(2+)-activated K(+) channels

We previouslycharacterized 1-ethyl-2-benzimidazolinone (1-EBIO), as well as theclinically useful benzoxazoles, chlorzoxazone (CZ), and zoxazolamine(ZOX), as pharmacological activators of the intermediate-conductanceCa²⁺-activated K⁺ channel, hIK1. The mechanismof activation of hIK1, as well as the highly homologoussmall-conductance, Ca²⁺-dependent K⁺ channel,rSK2, was determined following heterologous expression inXenopus oocytes using two-electrode voltage clamp (TEVC) and excised, inside-out patch-clamp techniques. 1-EBIO, CZ, and ZOX activated both hIK1 and rSK2 in TEVC and excised inside-out patch-clamp experiments. In excised, inside-out patches, 1-EBIO and CZ induced aconcentration-dependent activation of hIK1, with half-maximal (K_1/2) values of 84 µM and 98 µM, respectively.Similarly, CZ activated rSK2 with a K_1/2 of 87 µM. In the absence of CZ, the Ca²⁺-dependent activationof hIK1 was best fit with a K_1/2 of 700 nM and aHill coefficient (n) of 2.0. rSK2 was activated byCa²⁺ with a K_1/2 of 700 nM and ann of 2.5. Addition of CZ had no effect on either theK_1/2 or n for Ca²⁺-dependentactivation of either hIK1 or rSK2. Rather, CZ increased channelactivity at all Ca²⁺ concentrations(V_max). Event-duration analysis revealed hIK1 wasminimally described by two open and three closed times. Activation by1-EBIO had no effect on _o1, _o2, or_c1, whereas _c2 and _c3 werereduced from 9.0 and 92.6 ms to 5.0 and 44.1 ms, respectively. Inconclusion, we define 1-EBIO, CZ, and ZOX as the first known activatorsof hIK1 and rSK2. Openers of IK and SK channels may be therapeuticallybeneficial in cystic fibrosis and vascular diseases.